Compare · BSX vs EMBC
BSX vs EMBC
Side-by-side comparison of Boston Scientific Corporation (BSX) and Embecta Corp. (EMBC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and EMBC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 253.5x EMBC ($285.0M).
- Both names hit the wire about 11 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 9 for EMBC).
- Company
- Boston Scientific Corporation
- Embecta Corp.
- Price
- $49.86+1.73%
- $5.03+0.90%
- Market cap
- $72.26B
- $285.0M
- 1M return
- +9.58%
- -
- 1Y return
- -53.13%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 11
- Recent ratings
- 25
- 9
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
Latest EMBC
- Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.
- President and CEO Kurdikar Devdatt bought $140,937 worth of shares (30,000 units at $4.70), increasing direct ownership by 4% to 804,919 units (SEC Form 4)
- SVP and CFO Elguicze Jacob bought $93,360 worth of shares (20,000 units at $4.67), increasing direct ownership by 7% to 309,139 units (SEC Form 4)
- Pres, Pharm Svc&Prod Mgmt, CLO Mann Jeffrey Z bought $99,800 worth of shares (20,000 units at $4.99), increasing direct ownership by 8% to 262,915 units (SEC Form 4)
- Director Hombach Robert J. bought $223,848 worth of shares (45,000 units at $4.97), increasing direct ownership by 70% to 109,587 units (SEC Form 4)
- Chief Human Resources Officer Casner Jean covered exercise/tax liability with 1,480 shares, decreasing direct ownership by 2% to 85,915 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Embecta Corp.
- SEC Form 10-Q filed by Embecta Corp.
- Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results